FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 338:485-492 February 19, 1998 Number 8 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies can prevent osteoporosis in these women is also not clear.

Methods We studied the effect of 2.5 mg or 5 mg of alendronate per day or placebo on bone mineral density in 1174 postmenopausal women under 60 years of age. An additional 435 women who were prepared to receive a combination of estrogen and progestin were randomly assigned to one of the above treatments or open-label estrogen–progestin. The main outcome measure was the change in bone mineral density of the lumbar spine, hip, distal forearm, and total body measured annually for two years by dual-energy x-ray absorptiometry.

Results The women who received placebo lost bone mineral density at all measured sites, whereas the women treated with 5 mg of alendronate daily had a mean (±SE) increase in bone mineral density of 3.5±0.2 percent at the lumbar spine, 1.9±0.1 percent at the hip, and 0.7±0.1 percent for the total body (all P<0.001). Women treated with 2.5 mg of alendronate daily had smaller increases in bone mineral density. Alendronate did not increase bone mineral density of the forearm, but it slowed the loss. The responses to estrogen–progestin were 1 to 2 percentage points greater than those to the 5-mg dose of alendronate. Alendronate was well tolerated, with a safety profile similar to that of placebo or estrogen–progestin.

Conclusions Alendronate prevents bone loss in postmenopausal women under 60 years of age to nearly the same extent as estrogen–progestin.

Source Information

From the Division of Mineral Metabolism, City Hospital (D.H.), and the School of Community Health Sciences, University of Nottingham Medical School (C.E.D.C.), Nottingham, United Kingdom; the Center for Clinical and Basic Research, Ballerup, Denmark (C.C., P. Ravn); the Hawaii Osteoporosis Center, Honolulu (R.W., P. Ross); Oregon Osteoporosis Center, Providence Health System, Portland (M.M., A.B.); and Merck Research Laboratories, Rahway, N.J. (D.T., M.D., A.J.Y.).

Address reprint requests to Dr. Hosking at the Division of Mineral Metabolism, City Hospital, Hucknall Rd., Nottingham NG5 1PB, United Kingdom.

Full Text of this Article

This article has been cited by other articles:

• Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., San Martin, J. (2008). Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. J. Clin. Endocrinol. Metab. 93: 2149-2157 [Abstract] [Full Text]  
• MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., Grossman, J. (2008). Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. ANN INTERN MED 148: 197-213 [Abstract] [Full Text]  
• Ruggiero, S.L., Drew, S.J. (2007). Osteonecrosis of the Jaws and Bisphosphonate Therapy. J. Dent. Res. 86: 1013-1021 [Abstract] [Full Text]  
• Lopez-Granados, E., Temmerman, S. T., Wu, L., Reynolds, J. C., Follmann, D., Liu, S., Nelson, D. L., Rauch, F., Jain, A. (2007). Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc. Natl. Acad. Sci. USA 104: 5056-5061 [Abstract] [Full Text]  
• Michaud, L. B., Goodin, S. (2006). Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 63: 534-546 [Abstract] [Full Text]  
• Karlsson, M. K., Gerdhem, P., Ahlborg, H. G. (2005). The prevention of osteoporotic fractures. J Bone Joint Surg Br 87-B: 1320-1327 [Full Text]  
• McClung, M. R., Wasnich, R. D., Hosking, D. J., Christiansen, C., Ravn, P., Wu, M., Mantz, A. M., Yates, J., Ross, P. D., Santora, A. C. II, on behalf of the Early Postmenopausal Intervention, (2004). Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study. J. Clin. Endocrinol. Metab. 89: 4879-4885 [Abstract] [Full Text]  
• Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., Liberman, U. A., the Alendronate Phase III Osteoporosis Treatment S, (2004). Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women. NEJM 350: 1189-1199 [Abstract] [Full Text]  
• Evio, S., Tiitinen, A., Laitinen, K., Ylikorkala, O., Valimaki, M. J. (2004). Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis. J. Clin. Endocrinol. Metab. 89: 626-631 [Abstract] [Full Text]  
• Stakkestad, J A, Benevolenskaya, L I, Stepan, J J, Skag, A, Nordby, A, Oefjord, E, Burdeska, A, Jonkanski, I, Mahoney, P (2003). Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62: 969-975 [Abstract] [Full Text]  
• Doren, M., Nilsson, J.-A., Johnell, O. (2003). Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod 18: 1737-1746 [Abstract] [Full Text]  
• Brown, T. E. R. (2003). Osteoporosis: A Pharmacotherapy Update. Journal of Pharmacy Practice 16: 164-169 [Abstract]  
• Eichner, S. F, Lloyd, K. B, Timpe, E. M (2003). Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment. The Annals of Pharmacotherapy 37: 711-724 [Abstract] [Full Text]  
• Luckey, M. M., Gilchrist, N., Bone, H. G., Davie, M. W., de Villiers, T. J., Wu, M., Daifotis, A. G., Santora, A. C., Orloff, J. J. (2003). Therapeutic Equivalence of Alendronate 35 Milligrams Once Weekly and 5 Milligrams Daily in the Prevention of Postmenopausal Osteoporosis. Obstet Gynecol 101: 711-721 [Abstract] [Full Text]  
• Brown, J. P., Josse, R. G. (2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ 168: SF1-38 [Abstract] [Full Text]  
• Brown, J. P., Josse, R. G. (2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167: s1-34 [Abstract] [Full Text]  
• Nelson, H. D., Helfand, M., Woolf, S. H., Allan, J. D. (2002). Screening for Postmenopausal Osteoporosis: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 137: 529-541 [Abstract] [Full Text]  
• Bainbridge, K. E., Sowers, MF., Crutchfield, M., Lin, X., Jannausch, M., Harlow, S. D. (2002). Natural History of Bone Loss over 6 Years among Premenopausal and Early Postmenopausal Women. Am J Epidemiol 156: 410-417 [Abstract] [Full Text]  
• Dobrucali, A., Tobey, N. A., Awayda, M. S., Argote, C., Abdulnour-Nakhoul, S., Shao, W., Orlando, R. C. (2002). Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 283: G576-G586 [Abstract] [Full Text]  
• Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., Guyatt, G. (2002). II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women. Endocr. Rev. 23: 508-516 [Full Text]  
• Wells, G., Tugwell, P., Shea, B., Guyatt, G., Peterson, J., Zytaruk, N., Robinson, V., Henry, D., O'Connell, D., Cranney, A. (2002). V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women. Endocr. Rev. 23: 529-539 [Full Text]  
• Fiegl, M., Greil, R., Montoto, S., Blade, J., Montserrat, E., Jokl, D. H.-K., Kyle, R. A., Rajkumar, S. V., Melton, J. III (2002). Monoclonal Gammopathy of Undetermined Significance. NEJM 346: 2087-2088 [Full Text]  
• Donahue, J. G., Chan, K. A., Andrade, S. E., Beck, A., Boles, M., Buist, D. S. M., Carey, V. J., Chandler, J. M., Chase, G. A., Ettinger, B., Fishman, P., Goodman, M., Guess, H. A., Gurwitz, J. H., LaCroix, A. Z., Levin, T. R., Platt, R. (2002). Gastric and Duodenal Safety of Daily Alendronate. Arch Intern Med 162: 936-942 [Abstract] [Full Text]  
• Palomba, S., Orio, F. Jr., Colao, A., di Carlo, C., Sena, T., Lombardi, G., Zullo, F., Mastrantonio, P. (2002). Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab. 87: 1502-1508 [Abstract] [Full Text]  
• Wade, J. P. (2001). Rheumatology: 15. Osteoporosis. CMAJ 165: 45-50 [Full Text]  
• Khan, S. A., de Geus, C., Holroyd, B., Russell, A. S. (2001). Osteoporosis Follow-up After Wrist Fractures Following Minor Trauma. Arch Intern Med 161: 1309-1312 [Abstract] [Full Text]  
• Altkorn, D., Vokes, T. (2001). Treatment of Postmenopausal Osteoporosis. JAMA 285: 1415-1418 [Full Text]  
• Alexandersen, P., Riis, B. J., Stakkestad, J. A., Delmas, P. D., Christiansen, C. (2001). Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy. J. Clin. Endocrinol. Metab. 86: 755-760 [Abstract] [Full Text]  
• Johnston, C. C. Jr, Bjarnason, N. H., Cohen, F. J., Shah, A., Lindsay, R., Mitlak, B. H., Huster, W., Draper, M. W., Harper, K. D., Heath III, H., Gennari, C., Christiansen, C., Arnaud, C. D., Delmas, P. D. (2000). Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials. Arch Intern Med 160: 3444-3450 [Abstract] [Full Text]  
• Fogelman, I., Blake, G. M. (2000). Different Approaches to Bone Densitometry. JNM 41: 2015-2025 [Abstract] [Full Text]  
• Rodan, G. A., Martin, T. J. (2000). Therapeutic Approaches to Bone Diseases. Science 289: 1508-1514 [Abstract] [Full Text]  
• Ravn, P., Wasnich, R. D., Cizza, G. (2000). Long-Term Prevention of Bone Loss. ANN INTERN MED 133: 72-73 [Full Text]  
• Benson, K., Hartz, A. J. (2000). A Comparison of Observational Studies and Randomized, Controlled Trials. NEJM 342: 1878-1886 [Abstract] [Full Text]  
• Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., Reginster, J.-Y. (2000). Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial. J. Clin. Endocrinol. Metab. 85: 1895-1900 [Abstract] [Full Text]  
• Pfeilschifter, J., Diel, I. J. (2000). Osteoporosis Due to Cancer Treatment: Pathogenesis and Management. JCO 18: 1570-1593 [Abstract] [Full Text]  
• Ravn, P., Weiss, S. R., Rodriguez-Portales, J. A., McClung, M. R., Wasnich, R. D., Gilchrist, N. L., Sambrook, P., Fogelman, I., Krupa, D., Yates, A. J., Daifotis, A., Fuleihan, G. E.-H. (2000). Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal. J. Clin. Endocrinol. Metab. 85: 1492-1497 [Abstract] [Full Text]  
• Bauer, D. C., Black, D., Ensrud, K., Thompson, D., Hochberg, M., Nevitt, M., Musliner, T., Freedholm, D., for the Fracture Intervention Trial Research Group, (2000). Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial. Arch Intern Med 160: 517-525 [Abstract] [Full Text]  
• Ravn, P., Bidstrup, M., Wasnich, R. D., Davis, J. W., McClung, M. R., Balske, A., Coupland, C., Sahota, O., Kaur, A., Daley, M., Cizza, G., for the Early Postmenopausal Intervention Cohort S, (1999). Alendronate and Estrogen-Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial. ANN INTERN MED 131: 935-942 [Abstract] [Full Text]  
• Hall, W. J. (1999). Update in Geriatrics. ANN INTERN MED 131: 842-849 [Full Text]  
• Lindsay, R., Cosman, F., Lobo, R. A., Walsh, B. W., Harris, S. T., Reagan, J. E., Liss, C. L., Melton, M. E., Byrnes, C. A. (1999). Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial. J. Clin. Endocrinol. Metab. 84: 3076-3081 [Abstract] [Full Text]  
• McClung, M. R. (1999). Therapy for Fracture Prevention. JAMA 282: 687-689 [Full Text]  
• Col, N. F., Pauker, S. G., Goldberg, R. J., Eckman, M. H., Orr, R. K., Ross, E. M., Wong, J. B. (1999). Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women. Arch Intern Med 159: 1458-1466 [Abstract] [Full Text]  
• Ravn, P., Hosking, D., Thompson, D., Cizza, G., Wasnich, R. D., McClung, M., Yates, A. J., Bjarnason, N. H., Christiansen, C. (1999). Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study. J. Clin. Endocrinol. Metab. 84: 2363-2368 [Abstract] [Full Text]  
• Pinkerton, J. V., Santen, R. (1999). Alternatives to the Use of Estrogen in Postmenopausal Women. Endocr. Rev. 20: 308-320 [Abstract] [Full Text]  
• Cosman, F., Lindsay, R. (1999). Selective Estrogen Receptor Modulators: Clinical Spectrum. Endocr. Rev. 20: 418-434 [Abstract] [Full Text]  
• Miller, K. K., Klibanski, A. (1999). Amenorrheic Bone Loss. J. Clin. Endocrinol. Metab. 84: 1775-1783 [Full Text]  
• Santen, R. J., Petroni, G. R. (1999). Relative Versus Attributable Risk of Breast Cancer from Estrogen Replacement Therapy. J. Clin. Endocrinol. Metab. 84: 1875-1881 [Full Text]  
• Mbekeani, J. N., Slamovits, T. L., Schwartz, B. H., Sauer, H. L. (1999). Ocular Inflammation Associated With Alendronate Therapy. Arch Ophthalmol 117: 837-838 [Full Text]  
• Cummings, S. R., Black, D. M., Thompson, D. E., Applegate, W. B., Barrett-Connor, E., Musliner, T. A., Palermo, L., Prineas, R., Rubin, S. M., Scott, J. C., Vogt, T., Wallace, R., Yates, A. J., LaCroix, A. Z., for the Fracture Intervention Trial Research Group, (1998). Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures: Results From the Fracture Intervention Trial. JAMA 280: 2077-2082 [Abstract] [Full Text]  
• Levinson, W., Altkorn, D. (1998). Primary Prevention of Postmenopausal Osteoporosis. JAMA 280: 1821-1822 [Full Text]  
• Ragsdale, A. B., Barringer III, T. A., Anastasio, G. D. (1998). Alendronate Treatment to Prevent Osteoporotic Fractures. Arch Fam Med 7: 583-586 [Abstract] [Full Text]  
• Prior, J. C. (1998). Perimenopause: The Complex Endocrinology of the Menopausal Transition. Endocr. Rev. 19: 397-428 [Abstract] [Full Text]  
• Eastell, R. (1998). Treatment of Postmenopausal Osteoporosis. NEJM 338: 736-746 [Full Text]  
• (1998). Osteoporosis Prevention: Alendronate vs. HRT and Placebo. JWatch Women's Health 1998: 8-8 [Full Text]  
• (1998). Alendronate for Postmenopausal Women Without Osteoporosis. JWatch General 1998: 1-1 [Full Text]